 | • レポートコード：MRC2-11QY01373 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は院内肺炎（HAP）治療薬のグローバル市場について調査・分析したレポートです。種類別（抗菌、抗ウイルス、防カビ）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別院内肺炎（HAP）治療薬の競争状況、市場シェア ・世界の院内肺炎（HAP）治療薬市場：種類別市場規模 2015年-2020年（抗菌、抗ウイルス、防カビ） ・世界の院内肺炎（HAP）治療薬市場：種類別市場規模予測 2021年-2026年（抗菌、抗ウイルス、防カビ） ・世界の院内肺炎（HAP）治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の院内肺炎（HAP）治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の院内肺炎（HAP）治療薬市場分析：米国、カナダ ・ヨーロッパの院内肺炎（HAP）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの院内肺炎（HAP）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の院内肺炎（HAP）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの院内肺炎（HAP）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Merck、Mylan、Novartis、Teva Pharmaceutical Industries、AstraZeneca、Shinogi、Sun Pharmaceutical Industries、The Medicines Company、Theravance Biopharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.
Market Analysis and Insights: Global Hospital-Acquired Pneumonia (HAP) Drugs Market
The global Hospital-Acquired Pneumonia (HAP) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hospital-Acquired Pneumonia (HAP) Drugs Scope and Market Size
Hospital-Acquired Pneumonia (HAP) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hospital-Acquired Pneumonia (HAP) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hospital-Acquired Pneumonia (HAP) Drugs market is segmented into
Antibacterial
Antiviral
Antifungal
Segment by Application, the Hospital-Acquired Pneumonia (HAP) Drugs market is segmented into
Hospitals
Clinics
Others
Regional and Country-level Analysis
The Hospital-Acquired Pneumonia (HAP) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hospital-Acquired Pneumonia (HAP) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hospital-Acquired Pneumonia (HAP) Drugs Market Share Analysis
Hospital-Acquired Pneumonia (HAP) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hospital-Acquired Pneumonia (HAP) Drugs business, the date to enter into the Hospital-Acquired Pneumonia (HAP) Drugs market, Hospital-Acquired Pneumonia (HAP) Drugs product introduction, recent developments, etc.
The major vendors covered:
Pfizer
Merck
Mylan
Novartis
Teva Pharmaceutical Industries
AstraZeneca
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
1 Study Coverage
1.1 Hospital-Acquired Pneumonia (HAP) Drugs Product Introduction
1.2 Market Segments
1.3 Key Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Type
1.4.2 Antibacterial
1.4.3 Antiviral
1.4.4 Antifungal
1.5 Market by Application
1.5.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue 2015-2026
2.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales 2015-2026
2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hospital-Acquired Pneumonia (HAP) Drugs Competitor Landscape by Players
3.1 Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers
3.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers
3.2.1 Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hospital-Acquired Pneumonia (HAP) Drugs Revenue in 2019
3.2.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hospital-Acquired Pneumonia (HAP) Drugs Price by Manufacturers
3.4 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hospital-Acquired Pneumonia (HAP) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hospital-Acquired Pneumonia (HAP) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Type (2015-2020)
4.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020)
4.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2015-2020)
4.1.3 Hospital-Acquired Pneumonia (HAP) Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hospital-Acquired Pneumonia (HAP) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Application (2015-2020)
5.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020)
5.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2015-2020)
5.1.3 Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2015-2020)
5.2 Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hospital-Acquired Pneumonia (HAP) Drugs by Country
6.1.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
6.1.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Type
6.3 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs by Country
7.1.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
7.1.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Type
7.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs by Region
8.1.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region
8.1.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hospital-Acquired Pneumonia (HAP) Drugs by Country
9.1.1 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
9.1.2 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Type
9.3 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs by Country
10.1.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
10.1.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description and Business Overview
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.1.5 Pfizer Related Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description and Business Overview
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.2.5 Merck Related Developments
11.3 Mylan
11.3.1 Mylan Corporation Information
11.3.2 Mylan Description and Business Overview
11.3.3 Mylan Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.3.5 Mylan Related Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Description and Business Overview
11.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.4.5 Novartis Related Developments
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Corporation Information
11.5.2 Teva Pharmaceutical Industries Description and Business Overview
11.5.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.5.5 Teva Pharmaceutical Industries Related Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Description and Business Overview
11.6.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.6.5 AstraZeneca Related Developments
11.7 Shinogi
11.7.1 Shinogi Corporation Information
11.7.2 Shinogi Description and Business Overview
11.7.3 Shinogi Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.7.5 Shinogi Related Developments
11.8 Sun Pharmaceutical Industries
11.8.1 Sun Pharmaceutical Industries Corporation Information
11.8.2 Sun Pharmaceutical Industries Description and Business Overview
11.8.3 Sun Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.8.5 Sun Pharmaceutical Industries Related Developments
11.9 The Medicines Company
11.9.1 The Medicines Company Corporation Information
11.9.2 The Medicines Company Description and Business Overview
11.9.3 The Medicines Company Sales, Revenue and Gross Margin (2015-2020)
11.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.9.5 The Medicines Company Related Developments
11.10 Theravance Biopharma
11.10.1 Theravance Biopharma Corporation Information
11.10.2 Theravance Biopharma Description and Business Overview
11.10.3 Theravance Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.10.5 Theravance Biopharma Related Developments
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description and Business Overview
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
11.1.5 Pfizer Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hospital-Acquired Pneumonia (HAP) Drugs Market Estimates and Projections by Region
12.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hospital-Acquired Pneumonia (HAP) Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hospital-Acquired Pneumonia (HAP) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hospital-Acquired Pneumonia (HAP) Drugs Market Segments
Table 2. Ranking of Global Top Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Antibacterial
Table 5. Major Manufacturers of Antiviral
Table 6. Major Manufacturers of Antifungal
Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Regions 2015-2020 (K MT)
Table 10. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Hospital-Acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hospital-Acquired Pneumonia (HAP) Drugs as of 2019)
Table 16. Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Hospital-Acquired Pneumonia (HAP) Drugs Price (2015-2020) (USD/MT)
Table 19. Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Hospital-Acquired Pneumonia (HAP) Drugs Product Type
Table 21. Date of International Manufacturers Enter into Hospital-Acquired Pneumonia (HAP) Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Type (2015-2020)
Table 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Type (2015-2020)
Table 27. Hospital-Acquired Pneumonia (HAP) Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Application (2015-2020)
Table 30. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2015-2020) (K MT)
Table 31. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 35. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 37. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2015-2020) (K MT)
Table 39. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 43. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 45. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2015-2020) (K MT)
Table 47. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 51. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 53. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2015-2020) (K MT)
Table 55. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 59. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 61. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2015-2020) (K MT)
Table 63. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K MT)
Table 67. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K MT)
Table 69. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 73. Pfizer Product
Table 74. Pfizer Recent Development
Table 75. Merck Corporation Information
Table 76. Merck Description and Major Businesses
Table 77. Merck Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Merck Product
Table 79. Merck Recent Development
Table 80. Mylan Corporation Information
Table 81. Mylan Description and Major Businesses
Table 82. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Mylan Product
Table 84. Mylan Recent Development
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Major Businesses
Table 87. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Novartis Product
Table 89. Novartis Recent Development
Table 90. Teva Pharmaceutical Industries Corporation Information
Table 91. Teva Pharmaceutical Industries Description and Major Businesses
Table 92. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Teva Pharmaceutical Industries Product
Table 94. Teva Pharmaceutical Industries Recent Development
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Major Businesses
Table 97. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. AstraZeneca Product
Table 99. AstraZeneca Recent Development
Table 100. Shinogi Corporation Information
Table 101. Shinogi Description and Major Businesses
Table 102. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Shinogi Product
Table 104. Shinogi Recent Development
Table 105. Sun Pharmaceutical Industries Corporation Information
Table 106. Sun Pharmaceutical Industries Description and Major Businesses
Table 107. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Sun Pharmaceutical Industries Product
Table 109. Sun Pharmaceutical Industries Recent Development
Table 110. The Medicines Company Corporation Information
Table 111. The Medicines Company Description and Major Businesses
Table 112. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 113. The Medicines Company Product
Table 114. The Medicines Company Recent Development
Table 115. Theravance Biopharma Corporation Information
Table 116. Theravance Biopharma Description and Major Businesses
Table 117. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 118. Theravance Biopharma Product
Table 119. Theravance Biopharma Recent Development
Table 120. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 121. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 122. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 123. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 124. North America: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 125. North America: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 126. Europe: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 127. Europe: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 128. Asia Pacific: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 129. Asia Pacific: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 130. Latin America: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 131. Latin America: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Middle East and Africa: Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 133. Middle East and Africa: Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 134. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 135. Key Challenges
Table 136. Market Risks
Table 137. Main Points Interviewed from Key Hospital-Acquired Pneumonia (HAP) Drugs Players
Table 138. Hospital-Acquired Pneumonia (HAP) Drugs Customers List
Table 139. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Hospital-Acquired Pneumonia (HAP) Drugs Product Picture
Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Antibacterial Product Picture
Figure 4. Antiviral Product Picture
Figure 5. Antifungal Product Picture
Figure 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Others
Figure 10. Hospital-Acquired Pneumonia (HAP) Drugs Report Years Considered
Figure 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales 2015-2026 (K MT)
Figure 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region in 2019
Figure 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region in 2019
Figure 18. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Hospital-Acquired Pneumonia (HAP) Drugs Revenue in 2019
Figure 20. Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type in 2019
Figure 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type in 2019
Figure 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application in 2019
Figure 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application in 2019
Figure 30. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 31. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country in 2019
Figure 33. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 35. U.S. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 37. Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2019
Figure 39. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2019
Figure 40. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 41. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country in 2019
Figure 43. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 45. Germany Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 47. France Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 49. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 51. Italy Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 53. Russia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2019
Figure 55. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 57. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region in 2019
Figure 60. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 61. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 63. Japan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 65. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 67. India Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 69. Australia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 71. Taiwan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 73. Indonesia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 75. Thailand Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 77. Malaysia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 79. Philippines Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 81. Vietnam Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2019
Figure 84. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 85. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 89. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 91. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 93. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2019
Figure 95. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 97. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 101. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 103. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 105. U.A.E Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application in 2019
Figure 108. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 109. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 111. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
院内肺炎治療薬の世界市場（～2026年） Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus. Market An…- 市中肺炎（CAP）の世界市場（～2026年） Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and La…
- 医療関連感染（HAI）診断の世界市場（～2026年） Patients may catch infections during they are in the hospital, the hospital acquired infection test is used to diagnose those infections. The industry is anticipated to witness a significant growth in the next few years. One of the key factors driving industry growth is the rising geriatric populati…
- 院内感染治療の世界市場（～2026年） Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infec…
- 細菌性肺炎治療薬の世界市場（～2026年） Pneumonia is referred to as inflammatory, diseased condition of the lungs, which affects the alveoli of the lungs. Symptoms of pneumonia include chest pain, dry cough, trouble in breathing, and fever. Acquired pneumonia and health care-associated pneumonia are two types of pneumonia. Pneumonia affec…